Cangene wins anthrax antitoxin contract with U.S.

September 19, 2013

Cangene Corp. has received another contract — potentially for as much as $264 million — to provide its Anthrax Immune Globulin Intravenous (AIGIV) to the U.S. Department of Health and Human Services (HHS).

The contract is part of the U.S. government’s bio-defence program that Cangene has been participating in since 2007.

Click here for the story.

Share This Story